At the GBS Symposium, students presented their research in three formats: oral presentations, flash talk presentations, and a poster session. Students across all themes presented their research to ...
First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005) ...
As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another effort to improve treatment of the rare condition. Alongside a clinical data ...
Annexon, Inc. trades at ~$5.05, down ~22% since my last article in April 2024, indicating ongoing investor skepticism. The Q3 2024 earnings release and 10-Q reveal mixed prospects, impacting investor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results